RNF214 Activators

RNF214 can influence its E3 ubiquitin ligase activity through various mechanisms. Zinc pyrithione serves as a metallochaperone, which can enhance the proper folding and metal coordination required for RNF214's activity. Similarly, MG132, by inhibiting proteasome activity, can lead to the accumulation of ubiquitinated proteins. This accumulation can activate RNF214, as the cell may respond to the increased levels of ubiquitinated proteins by enhancing the ubiquitination process. Additionally, compounds like Thalidomide and PS-341, also known as Bortezomib, are known to disrupt the ubiquitin-proteasome pathway. Thalidomide can promote the degradation of proteins, potentially increasing RNF214 activity in this context. PS-341's role as a proteasome inhibitor can also lead to a feedback mechanism where RNF214 activity is upregulated to deal with the excess of proteins marked for degradation.

Chloroquine disrupts lysosomal function and autophagy, which can lead to increased proteasome-mediated degradation, possibly activating RNF214 to manage the protein load. Withaferin A and Piperlongumine can disrupt proteasomal function and increase reactive oxygen species levels, respectively. These changes can enhance the need for RNF214's ubiquitin ligase activity to maintain protein homeostasis. SMER3, by stimulating autophagy, can enhance the turnover of proteins, indirectly increasing RNF214 activity. Tunicamycin can induce ER stress and the unfolded protein response, which in turn can activate RNF214 to help clear the misfolded proteins. Eeyarestatin I inhibits ER-associated degradation, potentially increasing the demand on RNF214's ligase activity. Lastly, MLN4924 inhibits the NEDD8-activating enzyme and Geldanamycin binds to Hsp90, both of which can destabilize certain proteins, possibly resulting in an increased requirement for RNF214's function in targetin